Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:FRLNNASDAQ:HARPNASDAQ:PRTONASDAQ:RUBY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.53-1.8%$0.48$0.13▼$3.34$37.25M0.28996,438 shs273,815 shsFRLNFreeline Therapeutics$6.48$6.48$2.11▼$8.74$28.12M0.6612,055 shsN/AHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/APRTOProteon Therapeutics$3.05+8.2%$19.37$0.22▼$3.94$67.65M0.61.11 million shs262,559 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics-2.39%+3.44%-19.39%+67.82%-81.00%FRLNFreeline Therapeutics0.00%0.00%0.00%+1.09%+15.97%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.72%+301.29%PRTOProteon Therapeutics+8.16%+10.91%-23.56%+29.79%-2.87%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%+123.53%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics0.686 of 5 stars0.03.00.04.71.40.00.6FRLNFreeline Therapeutics0.0968 of 5 stars1.00.00.00.00.60.81.3HARPHarpoon Therapeutics1.2534 of 5 stars2.20.00.04.70.04.20.0PRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/AFRLNFreeline Therapeutics2.00Hold$4.83-25.41% DownsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsidePRTOProteon TherapeuticsN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest HARP, PRTO, FRLN, RUBY, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform2/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/AFRLNFreeline TherapeuticsN/AN/AN/AN/A$12.07 per shareN/AHARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ARUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)FRLNFreeline Therapeutics-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/AHARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest HARP, PRTO, FRLN, RUBY, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24FRLNFreeline TherapeuticsN/A1.95N/AHARPHarpoon TherapeuticsN/A1.891.89PRTOProteon TherapeuticsN/A5.985.98RUBYRubius TherapeuticsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%FRLNFreeline Therapeutics46.26%HARPHarpoon Therapeutics74.01%PRTOProteon Therapeutics23.03%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%FRLNFreeline Therapeutics1.90%HARPHarpoon Therapeutics17.00%PRTOProteon Therapeutics45.70%RUBYRubius Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableFRLNFreeline Therapeutics1524.34 million4.26 millionNot OptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableHARP, PRTO, FRLN, RUBY, and BCLI HeadlinesSourceHeadline‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)yahoo.com - April 26 at 3:33 AMVacant Rubius property generating interest after 1 year on marketpbn.com - April 18 at 1:01 AMSensorium Therapeutics Appoints Sam Rasty as Chief Business Officercitizentribune.com - April 17 at 8:01 PMVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'bizjournals.com - March 11 at 5:07 PMRubius Therapeutics Inc RUBYmorningstar.com - November 5 at 8:39 PM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorbostonglobe.com - October 16 at 7:58 AMRuby Dunne Biography & Moviestribute.ca - September 22 at 6:08 PMParenting Vlogger Ruby Franke Held Without Bail on Child Abuse Chargesoxygen.com - September 14 at 8:44 PMYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowtoday.com - September 8 at 6:33 PMRuby Gonzalesdailynews.com - August 21 at 8:30 AMRUBY - Rubius Therapeutics, Inc.uk.finance.yahoo.com - August 2 at 2:37 AMNorth American Morning Briefing: Alphabet, -2-morningstar.com - July 25 at 7:07 AMRuby Rivera, 23ABCturnto23.com - July 1 at 12:54 AMRuby Speakingcomedy.co.uk - June 23 at 3:11 PMRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternativesfinance.yahoo.com - March 2 at 1:59 AMWhatever happened to Ruby?infoworld.com - February 17 at 4:07 PMThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?marketwatch.com - February 14 at 7:55 PMWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?msn.com - February 14 at 9:54 AMThe Wrap: Ruby's moving to Congress Street, launching new French conceptyahoo.com - January 25 at 4:27 AMRuby Wax sparks concern from fans after posting video from hospital bedmirror.co.uk - January 12 at 12:51 AMRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookdailymail.co.uk - January 12 at 12:51 AMFormer Rubius CEO jumps to another Flagship spinoutfinance.yahoo.com - November 18 at 10:30 AMRubius Therapeutics lays off most of its staff, explores salefinance.yahoo.com - November 4 at 12:16 PMRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternativesfinance.yahoo.com - November 3 at 1:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Global benchmarks mostly climb despite worries about US economyApril 26, 2024 3:21 AMView Stock market today: Global benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentGE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsBuy the Dip in Paychex, Inc. for a Pay Check at RetirementApril 2, 2024 11:07 AMView Buy the Dip in Paychex, Inc. for a Pay Check at RetirementAll Headlines Company DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Rubius TherapeuticsNASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.